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Background: The uncertainties regarding dose similarities between basal long-acting insulin analogues remain.
Recent real-world studies indicate dose similarities between insulin detemir and insulin glargine, but further studies
are still warranted.
The aim of this study was to compare real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes
patients when administered once daily.
Methods: We analysed 536 patient cases from general practice (63%) and endocrinological outpatient clinics (37%).
A self-administered questionnaire completed by the treating physician was used to obtain data on patient
characteristics (gender, age, weight, height, latest HbA1c-value), daily doses, administration of and number of years
treated with insulin detemir and insulin glargine, concomitant insulin use and use of non-insulin anti-diabetic
medication. Both bivariate analyses and multivariate regression analyses were applied to examine whether there
were differences in the daily doses of insulin detemir and insulin glargine.
Results: There was no significant difference in the mean daily doses of insulin detemir (0.414 U/kg) and insulin
glargine (0.416 U/kg) (p = 0.4341). In multivariate regression analyses, age and BMI had a significant influence on
daily insulin dose with the dose increasing 0.003 U/kg (p = 0.0375) and 0.008 U/kg (p = 0.0003) with every 1
increment in age and BMI, respectively.
Conclusions: Dose similarities between insulin detemir and insulin glargine were seen in type 2 diabetes patients
when administered once daily. Thus, the use of insulin detemir and insulin glargine is not associated with different
medical costs if the price and treating algorithm are similar.
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Type 2 diabetes (T2D) is a chronic and potentially disab-
ling disease that affects around 350 million people world-
wide [1]. In Denmark, around 230,000 people have been
diagnosed with T2D corresponding to 8% of the popula-
tion aged 40+ years [2].
Glycemic control is important for the prevention of
diabetes-related complications in T2D patients, e.g. heart
disease, stroke, high blood pressure, blindness, kidney dis-
ease, neuropathy and amputations [3]. To obtain glycemic
control (e.g. HbA1c<7.5%), T2D patients benefit from* Correspondence: majk@cowi.dk
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reproduction in any medium, provided the ormeasures to improve insulin sensitivity such as diet and
exercise management [4]. When these measures fail, gly-
caemic goals can often be achieved with oral anti-diabetic
medication and/or injectable GLP-1 analogues. As the di-
sease progresses, the majority of patients will require in-
sulin to maintain HbA1c at desired target levels. Insulin
can be used concomitant to oral anti-diabetic medication/
GLP-1 analogues and as a part of either a basal only or a
basal-bolus regimen. Currently available basal insulin pre-
parations include the two long-acting insulin analogues -
insulin detemir (DET) [Levemir; Novo Nordisk, Denmark]
and insulin glargine (GLAR) [Lantus; Sanofi-Aventis,
USA] - as well as the intermediate-acting human insulin,
neutral protamine Hagedorn (NPH) insulin [5]. Comparedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Patient case included in the study.
Table 1 Mean daily dose of long-acting insulin analogue




Mean daily dose (U/kg) 0.414 0.416 0.4341
Jakobsen et al. BMC Endocrine Disorders 2012, 12:21 Page 2 of 6
http://www.biomedcentral.com/1472-6823/12/21to intermediate-acting insulin (NPH), long-acting insu-
lin analogues offer a prolonged duration of action and re-
duced risk of hypoglycaemic events, especially nocturnal
events [6-11].
Other studies - including both clinical trials [12-15] and
real-world studies [16;17] - have found that the use of
DET and GLAR in T2D patients results in comparable
HbA1c improvements and a similar low risk of hypogly-
caemia versus NPH, whereas DET is associated with signi-
ficantly less weight gain than GLAR [12-18].
However, uncertainties with regard to dose similarities
between DET and GLAR remain. The attempt to com-
pare daily doses of DET and GLAR has been compli-
cated by different treatment algorithms where DET is
dosed once or twice daily whereas GLAR is dosed only
once daily. Thus, existing clinical trials comparing DET
and GLAR provide inconsistent results in terms of dose-
related findings. Some studies have concluded that the
daily DET dose is on average higher than the daily
GLAR dose [12;15] whereas others find no significant
differences [14]. Recent real-world studies indicate dose
similarities between DET and GLAR [19-21].
The aim of this study was - in routine clinical settings
in Denmark - to compare daily doses of DET and GLAR
in T2D patients when administered once daily.
Methods
Data collection
Data was collected by a self-administered questionnaire
to general practitioners (GPs) and specialists. The ques-
tionnaire included information on patient characteristics
(gender, age, weight, height, latest HbA1c-value), use of
insulin and non-insulin anti-diabetic medication. In total,
490 GP offices were contacted by letter (72), telephone
(146) or online (272), and 86 endocrinological outpatient
clinics were contacted by telephone. The GPs were asked
to fill in a questionnaire for each of their T2D patients
treated with either DET or GLAR based on information
registered in their computer system. Data from GPs were
collected from 6 December 2010 to 4 February 2011. The
specialists were asked to fill in a questionnaire for each of
their T2D patients treated with DET or GLAR whom they
were in contact with from 29 November to 10 December
2010. In total, 79 GP offices and 25 endocrinological out-
patient clinics participated in the study.
As illustrated in Figure 1, the participating GP offices
and specialists returned 640 questionnaires and 299 ques-
tionnaires, respectively, providing data on 939 patient ca-
ses in total. Among the 939 patient cases, 360 were found
ineligible because DET or GLAR was administered more
than once daily or data on number of daily injections was
not available. Furthermore, 43 patient cases were excluded
because of missing body weight data. In total, 536 patient
cases were included in the analyses.Statistical methods
Analyses were performed using the statistical package
SAS 9.2 for Windows (SAS Institute, Cary, NC, USA).
Both bivariate analyses and multivariate linear regression
analyses were applied to examine possible differences in
the daily doses of DET and GLAR. The following back-
ground variables were included as covariates in the mul-
tivariate regression analyses: gender, age, height, BMI,
region, HbA1c-value, prescriber (GP or specialist), conco-
mitant insulin use, non-insulin anti-diabetic medication,
number of years treated with DET or GLAR and number
of years on anti-diabetic medication. Two models were
estimated - a small and a larger model in terms of number
of covariates. Patient cases with missing values were ex-
cluded from the analyses. All statistical tests were per-
formed at 5% significance level.
Ethics
Approval from an ethics committee was not required by
Danish law since the study did not involve collection
of or research on biological material. Furthermore, as
no personal data defined as any information relating
to an identified or identifiable patient was obtained in the
questionnaires to GPs and specialists (e.g. CPR number
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could refer to a single patient), no informed consent was
necessary by Danish law. A waiver for ethics approval has









≥50 years and <60 years 96
≥65 years 106
Mean weight (kilos) 86
Mea height (cm) 172
Mean BMI (kilos/m2) 29.1
HbA1c value (%) 8.0 (63.9 mmol/
Mean number of years on antdiabetic medication 11
Mean number of years on Determir/Glargine 2.1
Geography
North Denmark Region 22
Central Denmark Region 63
Southern Denmark Region 66
Region Sealand 43












At least one product 159
Biguanides 146
Sulfonomides 15
Glitazoner (TZD) and combinations 0




There was no significant difference in the mean daily
doses of DET and GLAR (see Table 1). The mean dailyin analogue DET and GLAR
Glargine P-value
(%) N (%) (χ2-test)
47% 285 53%
40% 130 46% 0.2099
60% 155 54%
60 0.7123
20% 63 22% 0.4629
38% 103 36% 0.6145




mol) 8.2 (66.1 mmol/mol) 0.5602
10 0.068
2.2 0.2672
9% 26 9% 0.8849
25% 32 11% 0.0000
26% 85 30% 0.3647
17% 44 15% 0.5959
23% 98 34% 0.0029
71% 159 56% 0.0002
29% 126 44%
44% 114 40% 0.3703
31% 82 29% 0.4959
6% 4 1% 0.0024
0% 4 1% 0.0596
0% 3 1% 0.1031
7% 22 8% 0.8096
63% 188 66% 0.5267
58% 173 61% 0.5509
6% 16 6% 0.8578
0% 0 0%
3% 4 1% 0.1637
10% 41 14% 0.1595
0% 1 0% 0.3476
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dose of GLAR (n= 285) was 0.416 U/kg (p= 0.4341).
Background characteristics of the study population are
shown in Table 2. No significant differences between DET
and GLAR patients were found with respect to gender,
age, weight, height, BMI, latest HbA1c-value and use of
non-insulin anti-diabetic medication. The percentage of
DET patients was larger among GPs (71%) than among
specialists (56%) (p= 0.0002). Furthermore, significant or
borderline significant differences were found in concomi-
tant insulin use with more DET patients treated with
Actrapid and more GLAR patients treated with Insuman
Rapid. However, the overall percentage of T2D patients in
the study population treated with these products was very
small, and it is unclear whether such differences exist for
T2D patients in general.
Multivariate regression analysis
The results of the multivariate regression analyses are re-
ported in Table 3. In both models, type of long-acting in-
sulin analogue used was not significant, i.e. the daily doses
of DET and GLAR did not differ significantly between
T2D patients when administered once daily and when ta-
king into account other factors that may influence insulin
utilisation.
Age and BMI, on the other hand, had a significant in-
fluence on the daily insulin dose with the dose increa-
sing 0.003 U/kg (p = 0.0375) and 0.008 U/kg (p = 0.0003)Table 3 Multivariate regression models of daily dose of long-







Number of years on antidiabetic modification






Capital region of Denmark
Prescriber (GP = ,specialist)
Concomitant insulin use (none= 0, at least one other product = 1)
Non-insulin antidiabetic medication (none= 0, at least one other product = 1)with every 1 increment in age and BMI, respectively. The
correlation between BMI and insulin dose is well-
established. Obese T2D patients require larger doses of
insulin to achieve metabolic control than lean T2D
patients as they are more insulin resistant [4].
No other covariates included in the models showed
robust statistical correlation with daily insulin dose. Nei-
ther concomitant insulin use nor use of non-insulin anti-
diabetic medication was significant. This is probably a
consequence of effects pulling in different directions. On
the one hand, concomitant insulin use and use of non-
insulin anti-diabetic medication are correlated with dis-
ease severity and thus daily dose of DET or GLAR. On the
other hand, these products may act as substitutes for
long-acting insulin analogues and thus reduce the daily
dose of DET and GLAR.
Discussion
This study contributes with real-life evidence of dose
similarities between DET and GLAR in T2D patients in
Denmark. No differences in daily doses of DET and GLAR
were identified when administered once daily and when
taking into account different factors that may influence
insulin utilisation. Thus, use of DET and GLAR is not
associated with different medical costs if the price and
treatment algorithm are similar.
The results of this study are consistent with recent
real-world studies from Europe and the US, which alsoacting insulin analogue DET and GLAR (U/kg)
Model 1
(N-485, Adj R2 = 0.7636)
Model 2
(N-458, Adj R2 = 0.7699)
Coefficient P-value (t-test) Coefficient P-value (t-test)
−0.0010 0.9609 0.0009 0.9687
0.0522 0.0884
0.0026 <.0001 0.0019 0.0375*
−0.0031 0.0905











0.0295 0.2177 0.0278 0.0210*
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and GLAR in T2D patients [19-21].
The results of this study are also in line with available
data from the Danish Medicines Agency on redeemed
prescriptions to individuals in 2008 and 2009, which do
not indicate differences in daily doses of DET and GLAR
(unpublished observations).
The evidence from clinical trials comparing DET and
GLAR is inconsistent in terms of dose-related findings.
This study is consistent with the results of a clinical trial
including 385 American T2D patients in a basal-bolus
regimen, which did not find significant dose differences
between DET and GLAR [14]. On the other hand, our
results conflict with the results of a clinical trial inclu-
ding 582 European T2D patients in a basal regimen [15]
and a clinical trial including 319 European and American
T2D patients in a basal-bolus regimen [12]. Both studies
found that the mean daily dose of DET was higher than
the mean daily dose of GLAR. However, these differences
were mainly due to differences in treatment algorithms
with more DET patients on twice daily dosing compared
to GLAR patients.
Clinical trials are often considered the gold standard,
but they do not necessarily reflect clinical practice, and
furthermore, clinical practice may differ between coun-
tries. Thus, real-world studies such as the present study
play an important role in terms of providing evidence of
actual insulin utilisation.
A major strength of this study is that data was col-
lected directly from the treating physician giving precise
information on prescribed insulin dose in units per day.
The daily dose prescribed by the treating physician is
not necessarily the same as the dose actually used by the
patient. However, it does not seem likely that there are
differences between DET and GLAR patients with regard
to compliance, and therefore this should not influence
the main conclusion of no significant dose differences
between DET and GLAR. Overall, the risk of informa-
tion bias is considered low in this study compared to
other real-world studies where the daily insulin dose is
calculated based on dispensing data [19-21].
Dose comparisons were strictly performed for the same
treatment algorithm (once daily dosing of DET or GLAR)
in accordance with the aim of the study (as it otherwise
would include off-label use of GLAR). Patients with two
or more daily injections − of which the majority was DET
patients − were excluded in the analyses presented here
which could be regarded as a limitation towards the ability
to conclude on cost differences. However, multivariate re-
gression analyses were performed with these patients
included. The analyses confirmed the expected positive
correlation between number of daily injections and daily
insulin dose as well as dose similarities between DET and
GLAR when administered twice daily (data not shown).The overall conclusion remained unchanged, i.e. no diffe-
rences in daily doses of DET and GLAR were identified
when taking into account different factors that may in-
fluence insulin utilisation, including treatment algorithm.
A limitation of this study is the sensitivity to selection
bias as the participating GP offices and specialists were
not selected randomly. However, the study population is
large and diverse which makes it highly probable that
the main conclusion of no significant dose differences
between DET and GLAR in a once daily regime is repre-
sentative for all T2D patients in Denmark.
Another limitation concerns the possibility of residual
confounding. The existence of co-morbidities in T2D pa-
tients may influence insulin utilisation, but was not in-
cluded in the multivariate regression models as data was
not available. However, it is not likely that this would have
changed the main conclusion of no significant dose diffe-
rences between DET and GLAR as there are no compel-
ling reasons to assume that co-morbidities differ between
T2D patients treated with DET and GLAR.Conclusions
Based on this study, we conclude that the real-life daily
doses of DET and GLAR in Danish T2D patients are
similar when administered once daily. Thus, neither DET
nor GLAR should be preferred over the other on eco-
nomic grounds with reference to possible dose differences
as long as the price and treating algorithm are similar.
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